Fig. 3
From: Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Characterisation of the orthotopic U87-MGvIII model. A In vivo axial T2-weighted MRI image and corresponding axial, coronal, and sagittal PET/CT images of the orthotopic U87-MGvIII tumour 3 h post-injection of the 18F-AlF-NOTA-ZEGFR:03115 compared to the haematoxylin/eosin staining. B In vivo uptake values 1, 3, and 5 h after i.v. injection of the radiotracer (mean ± SEM), measured as % ID/g50 and % ID/gmax. C In vivo axial T2-weighted MRI image and corresponding ex vivo photography and fluorescence image 5 days after tumour cell engraftment (tumour diameter, 2.7 mm). Brain collection and fluorescence imaging were performed 1 h after i.v. injection of 18 μg of ZEGFR:03115-IR700. Haematoxylin/eosin staining and near-infrared image of ZEGFR:03115-IR700 were performed on the consecutive brain sections. The EGFR immunostaining confirmed the high level of EGFR